These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35034868)

  • 1. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.
    Caimi PF; Ardeshna KM; Reid E; Ai W; Lunning M; Zain J; Solh M; Kahl BS; Hamadani M
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e335-e339. PubMed ID: 35034868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
    Goparaju K; Caimi PF
    Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
    Xu B
    Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
    Ahmed N; Hamadani M
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1313-1320. PubMed ID: 34597242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 6. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
    Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
    Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
    Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
    Haematologica; 2024 Oct; 109(10):3314-3326. PubMed ID: 38721745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Juárez-Salcedo LM; Nimkar S; Corazón AM; Dalia S
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
    Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine.
    Caimi PF; Hamadani M; Carlo-Stella C; Nickaeen M; Jordie E; Utsey K; Knab T; Zammarchi F; Cucchi D; Pantano S; Havenith K; Wang Y; Boni J
    EJHaem; 2024 Feb; 5(1):76-83. PubMed ID: 38406517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.
    Sermer D; Elavalakanar P; Abramson JS; Palomba ML; Salles G; Arnason J
    Blood Rev; 2023 Jan; 57():101002. PubMed ID: 35989138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma.
    Lownik J; Boiarsky J; Birhiray R; Merchant A; Mead M
    Clin Cancer Res; 2024 Jul; 30(14):2895-2904. PubMed ID: 38661647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
    Dodero A; Bramanti S; Di Trani M; Pennisi M; Ljevar S; Chiappella A; Massimo M; Guidetti A; Corrado F; Nierychlewska PM; Di Rocco A; Lorenzini D; Daoud R; De Philippis C; Santoro A; Carlo-Stella C; Corradini P
    Br J Haematol; 2024 Jan; 204(1):151-159. PubMed ID: 37690811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
    de Ramon Ortiz C; Wang S; Stathis A; Bertoni F; Zenz T; Novak U; Simonetta F
    Hematol Oncol; 2024 Jan; 42(1):e3237. PubMed ID: 37937474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Baek GT; Huang IJ; Gopal AK
    Cancer; 2023 Aug; 129(15):2279-2283. PubMed ID: 37208793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
    J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.